| scholarly article | Q13442814 |
| P356 | DOI | 10.1053/J.GASTRO.2005.04.009 |
| P698 | PubMed publication ID | 16012942 |
| P50 | author | Ryosuke Tateishi | Q37838027 |
| P2093 | author name string | Masao Omata | |
| Takao Kawabe | |||
| Takashi Ishikawa | |||
| Haruhiko Yoshida | |||
| Shinpei Sato | |||
| Shuichiro Shiina | |||
| Shuntaro Obi | |||
| Takuma Teratani | |||
| Yukihiro Koike | |||
| Tomonori Fujishima | |||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | randomized controlled trial | Q1436668 |
| P1104 | number of pages | 9 | |
| P304 | page(s) | 122-130 | |
| P577 | publication date | 2005-07-01 | |
| P1433 | published in | Gastroenterology | Q4039279 |
| P1476 | title | A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma | |
| P478 | volume | 129 |
| Q28392783 | 2014 KLCSG-NCC Korea Practice Guideline for the Management of Hepatocellular Carcinoma |
| Q28394414 | 2014 Korean Liver Cancer Study Group-National Cancer Center Korea practice guideline for the management of hepatocellular carcinoma |
| Q64272871 | 2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma |
| Q91599660 | 2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma |
| Q28067517 | A Recent Advance in Image-Guided Locoregional Therapy for Hepatocellular Carcinoma |
| Q42064611 | A Surgical Perspective on Targeted Therapy of Hepatocellular Carcinoma |
| Q33632388 | A case of gouty arthritis following percutaneous radiofrequency ablation for hepatocellular carcinoma |
| Q33916361 | A multidisciplinary approach to the management of hepatocellular carcinoma |
| Q39410834 | Ablation for hepatocellular carcinoma: validating the 3-cm breakpoint. |
| Q91654805 | Ablative therapies for hepatic and biliary tumors: endohepatology coming of age |
| Q56889781 | Accelerated Progression of Hepatocellular Carcinoma during Immunosuppressive Therapy with Abatacept for Rheumatoid Arthritis |
| Q42004327 | Accomplishments in 2007 in the management of hepatobiliary cancers. |
| Q42323705 | Addition of transcatheter arterial chemoembolization decreased local recurrence but had no survival benefit to percutaneous ethanol injection therapy for patients with small hepatocellular carcinoma: A multicenter randomized control study |
| Q38371669 | An overview of loco-regional treatments in patients and mouse models for hepatocellular carcinoma. |
| Q42631803 | Analysis of recurrence pattern and its influence on survival outcome after radiofrequency ablation of hepatocellular carcinoma |
| Q35780838 | Application of the Barcelona Clinic Liver Cancer therapeutic strategy and impact on survival |
| Q37962184 | Are patients with Child's A cirrhosis and hepatocellular carcinoma appropriate candidates for liver transplantation? |
| Q41962614 | Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update |
| Q30479629 | Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma |
| Q92103963 | Assessment of hepatocellular carcinoma treatment response with LI-RADS: a pictorial review |
| Q35567684 | Assessment of radiofrequency ablation margin by MRI-MRI image fusion in hepatocellular carcinoma |
| Q33432267 | Bone marrow metastasis presenting as bicytopenia originating from hepatocellular carcinoma. |
| Q26766707 | Brazilian society of hepatology recommendations for the diagnosis and treatment of hepatocellular carcinoma |
| Q36753380 | Characteristics and quality of randomized controlled trials in the treatment of hepatocellular carcinoma |
| Q38391223 | Chemoembolization combined with radiofrequency ablation for patients with hepatocellular carcinoma larger than 3 cm: a randomized controlled trial |
| Q58215194 | Clinical Development and Future Direction for the Treatment of Hepatocellular Carcinoma |
| Q35163337 | Clinical Presentation of Hepatocellular Carcinoma (HCC) in Asian-Americans Versus Non-Asian-Americans |
| Q40706736 | Clinical features and natural history of portal vein thrombosis after radiofrequency ablation for hepatocellular carcinoma in Japan |
| Q40240706 | Clinical features of hemodialysis patients treated for hepatocellular carcinoma: Comparison between resection and radiofrequency ablation |
| Q53452462 | Clinical outcome of hepatectomy for hepatocellular carcinomas≤2 cm |
| Q26864261 | Clinical outcome of small hepatocellular carcinoma after different treatments: a meta-analysis |
| Q53505408 | Clinical results of proton beam therapy for hepatocellular carcinoma over 5 cm. |
| Q53477048 | Clinical utility of multipolar ablation with a 3-D simulator system for patients with liver cancer. |
| Q51738380 | Combined radiofrequency ablation and ethanol injection with a multipronged needle for the treatment of medium and large hepatocellular carcinoma. |
| Q36980629 | Combining locoregional therapies in the treatment of hepatocellular carcinoma |
| Q28067018 | Comparative Efficacy of Interventional Therapies for Early-stage Hepatocellular Carcinoma: A PRISMA-compliant Systematic Review and Network Meta-analysis |
| Q35033273 | Comparative effectiveness of radiofrequency ablation with or without transarterial chemoembolization for hepatocellular carcinoma |
| Q57812099 | Comparative efficacy of treatment strategies for hepatocellular carcinoma: systematic review and network meta-analysis |
| Q51703108 | Comparing hepatic resection and transarterial chemoembolization for Barcelona Clinic Liver Cancer (BCLC) stage B hepatocellular carcinoma: change for treatment of choice? |
| Q37716505 | Comparing the long-term efficacy of standard and combined minimally invasive procedures for unresectable HCC: a mixed treatment comparison |
| Q93009354 | Comparison of Liver Transplant Wait-List Outcomes Among Patients With Hepatocellular Carcinoma With Public vs Private Medical Insurance |
| Q64916058 | Comparison of diffusion kurtosis imaging versus diffusion weighted imaging in predicting the recurrence of early stage single nodules of hepatocellular carcinoma treated by radiofrequency ablation. |
| Q37584677 | Comparison of high-intensity focused ultrasound therapy and radiofrequency ablation for recurrent hepatocellular carcinoma |
| Q42175640 | Comparison of improved prognosis between hepatitis B- and hepatitis C-related hepatocellular carcinoma |
| Q30410578 | Comparison of percutaneous ablation technologies in the treatment of malignant liver tumors |
| Q36401584 | Comparison of percutaneous radiofrequency ablation and CyberKnife(®) for initial solitary hepatocellular carcinoma: A pilot study |
| Q34113019 | Comparison of percutaneous radiofrequency thermal ablation and surgical resection for small hepatocellular carcinoma |
| Q38190868 | Comparison of the therapeutic outcomes between surgical resection and percutaneous ablation for small hepatocellular carcinoma |
| Q41130270 | Concurrent and subsequent radiofrequency ablation combined with hepatectomy for hepatocellular carcinomas |
| Q30478164 | Contrast-enhanced harmonic ultrasound imaging in ablation therapy for primary hepatocellular carcinoma |
| Q48962335 | Copper chelation by trientine dihydrochloride inhibits liver RFA-induced inflammatory responses in vivo |
| Q53085469 | Coronal reformatted CT images contribute to the precise evaluation of the radiofrequency ablative margin for hepatocellular carcinoma. |
| Q80426414 | Cost of radiofrequency ablation in the treatment of hepatic malignancies |
| Q38173739 | Critical appraisal of the role of sorafenib in the management of hepatocellular carcinoma |
| Q92344068 | Current State of Liver-Directed Therapies and Combinatory Approaches with Systemic Therapy in Hepatocellular Carcinoma (HCC) |
| Q57763108 | Current Status of Hepatocellular Carcinoma Treatment in Japan |
| Q26801211 | Current and future treatments for hepatocellular carcinoma |
| Q87604943 | Current management of hepatocellular carcinoma |
| Q37821277 | Current status of radiofrequency ablation of hepatocellular carcinoma |
| Q36769640 | Current status of sonographically guided radiofrequency ablation techniques |
| Q38257936 | Current treatment for small (< 5 cm) hepatocellular carcinoma: evolving roles for ablation and resection |
| Q27312299 | Design and development of a robotized system coupled to µCT imaging for intratumoral drug evaluation in a HCC mouse model |
| Q60936575 | Development of asialoglycoprotein receptor directed nanoparticles for selective delivery of curcumin derivative to hepatocellular carcinoma |
| Q26741205 | Diabetes mellitus and metformin in hepatocellular carcinoma |
| Q44481786 | Diagnosis of and therapy for hepatocellular carcinoma |
| Q26999043 | Diagnostic and therapeutic management of hepatocellular carcinoma |
| Q36049920 | Diagnostic value for extrahepatic metastases of hepatocellular carcinoma in positron emission tomography/computed tomography scan |
| Q30448573 | Discrimination between neoplastic and non-neoplastic lesions in cirrhotic liver using contrast-enhanced ultrasound |
| Q44680235 | Drastically reduced neoplastic seeding related to radiofrequency ablation for hepatocellular carcinoma. |
| Q37140022 | Early detection of liver cancer: diagnosis and management |
| Q53356536 | Early diffuse recurrence of hepatocellular carcinoma after percutaneous radiofrequency ablation: analysis of risk factors. |
| Q36348796 | Early liver cancer: concepts, diagnosis, and management |
| Q33857944 | Effect of treatment support on preventing local recurrence of hepatocellular carcinoma directly adjacent to the diaphragm |
| Q50458927 | Effectiveness of combined (131)I-chTNT and radiofrequency ablation therapy in treating advanced hepatocellular carcinoma. |
| Q39426115 | Effects of radiofrequency ablation versus other ablating techniques on hepatocellular carcinomas: a systematic review and meta-analysis |
| Q35900872 | Efficacy and Safety of Radiofrequency Ablation Combined with Transcatheter Arterial Chemoembolization for Hepatocellular Carcinomas Compared with Radiofrequency Ablation Alone: A Time-to-Event Meta-Analysis |
| Q30367323 | Efficacy and safety of endoscopic ultrasonography-guided interventional treatment for refractory malignant left-sided liver tumors: a case series of 26 patients |
| Q47880601 | Efficacy of Ablation Therapy for Secondary Hyperparathyroidism by Ultrasound Guided Percutaneous Thermoablation |
| Q62489408 | Efficacy of Hepatic Resection vs. Radiofrequency Ablation for Patients With Very-Early-Stage or Early-Stage Hepatocellular Carcinoma: A Population-Based Study With Stratification by Age and Tumor Size |
| Q59353991 | Efficacy of Nucleoside Analogs for Chronic Hepatitis B Virus-Related Hepatocellular Carcinoma After Curative Treatment: A Meta-Analysis |
| Q64235272 | Efficacy of radiofrequency ablation and microwave ablation in the treatment of thoracic cancer: A systematic review and meta-analysis |
| Q36950974 | Efficacy of radiofrequency ablation of hepatocellular carcinoma associated with chronic liver disease without cirrhosis |
| Q37889718 | Efficacy of surgical microwave therapy in patients with unresectable hepatocellular carcinoma |
| Q26851272 | Emerging trends in hepatocellular carcinoma: focus on diagnosis and therapeutics |
| Q85562799 | Endoscopic versus open radiofrequency ablation for treatment of small hepatocellular carcinoma |
| Q35171592 | Ethanol injection is highly effective for hepatocellular carcinoma smaller than 2 cm. |
| Q79448377 | Ethanol versus radiofrequency ablation for the treatment of small hepatocellular carcinoma in patients with cirrhosis: a retrospective study of efficacy and cost |
| Q42538510 | Evaluation of in vivo efficacy of radiofrequency ablation with D-sorbitol in animal liver |
| Q36662547 | Evaluation of the in vivo efficiency and safety of hepatic radiofrequency ablation using a 15-G Octopus® in pig liver |
| Q46178855 | Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable? |
| Q37353089 | Evidence-based diagnosis and locoregional therapy for hepatocellular carcinoma |
| Q50530131 | Expression of keratin 19 is related to high recurrence of hepatocellular carcinoma after radiofrequency ablation. |
| Q44670065 | Expressions of hypoxia-inducible factor-1 and epithelial cell adhesion molecule are linked with aggressive local recurrence of hepatocellular carcinoma after radiofrequency ablation therapy. |
| Q35161032 | Factors influencing distant recurrence of hepatocellular carcinoma following combined radiofrequency ablation and transarterial chemoembolization therapy in patients with hepatitis C. |
| Q83078598 | HBV-related HCC, clinical issues and therapy |
| Q35081499 | Halofuginone suppresses the lung metastasis of chemically induced hepatocellular carcinoma in rats through MMP inhibition. |
| Q36235405 | Hepatic radiofrequency ablation: in vivo and ex vivo comparisons of 15-gauge (G) and 17-G internally cooled electrodes |
| Q58021316 | Hepatocellular Carcinoma |
| Q28071444 | Hepatocellular Carcinoma: The Role of Interventional Oncology |
| Q29616359 | Hepatocellular carcinoma |
| Q83710870 | Hepatocellular carcinoma with extrahepatic metastasis: clinical features and prognostic factors |
| Q26783881 | Hepatocellular carcinoma: From clinical practice to evidence-based treatment protocols |
| Q35668716 | Hepatocellular carcinoma: From diagnosis to treatment |
| Q37235259 | Hepatocellular carcinoma: defining the place of surgery in an era of organ shortage |
| Q36171275 | Hepatocellular carcinoma: natural history, current management, and emerging tools |
| Q37678972 | Hepatocellular carcinoma: new options for image-guided ablation |
| Q34508914 | High-dose stereotactic body radiotherapy correlates increased local control and overall survival in patients with inoperable hepatocellular carcinoma |
| Q82423711 | Hypofractionated Stereotactic Body Radiotherapy for Primary and Metastatic Liver Tumors Using the Novalis Image-Guided System: Preliminary Results regarding Efficacy and Toxicity |
| Q38324277 | Image-guided ablation of primary liver and renal tumours |
| Q37370024 | Image-guided percutaneous ablation therapies for hepatocellular carcinoma |
| Q26772233 | Imaging Modalities for Assessment of Treatment Response to Nonsurgical Hepatocellular Carcinoma Therapy: Contrast-Enhanced US, CT, and MRI |
| Q30458257 | Imaging and Imaging-Guided Interventions in the Diagnosis and Management of Hepatocellular Carcinoma (HCC)-Review of Evidence |
| Q54222559 | Implication of frequent local ablation therapy for intrahepatic recurrence in prolonged survival of patients with hepatocellular carcinoma undergoing hepatic resection: an analysis of 610 patients over 16 years old. |
| Q46339113 | Influence of serum HBV DNA load on recurrence of hepatocellular carcinoma after treatment with percutaneous radiofrequency ablation |
| Q55133340 | Integrating interventional oncology in the treatment of liver tumors. |
| Q35626764 | Intermediate hepatocellular carcinoma: How to choose the best treatment modality? |
| Q37734190 | Interventional radiological treatment of hepatocellular carcinoma |
| Q35675131 | Interventional radiological treatment of hepatocellular carcinoma: an update |
| Q80765863 | Intrahepatic distant recurrence after radiofrequency ablation for a single small hepatocellular carcinoma: risk factors and patterns |
| Q37795703 | Is it time to reconsider the BCLC/AASLD therapeutic flow‐chart? |
| Q36349931 | Knowledge of hepatocellular carcinoma screening guidelines and clinical practices among gastroenterologists |
| Q33966323 | Laparoscopic repair of a diaphragmatic hernia associated with radiofrequency ablation for hepatocellular carcinoma: lessons from a case and the review of the literature |
| Q51398248 | Limitation of repeated radiofrequency ablation in hepatocellular carcinoma: proposal of a three (times) × 3 (years) index. |
| Q95423570 | Linear enhancement after radio-frequency ablation for hepatocellular carcinoma: is it a sign of recurrence? |
| Q38576929 | Liver Ablation: Best Practice. |
| Q38078347 | Liver Transplantation for HCC: A Review |
| Q53475196 | Liver resection or combined chemoembolization and radiofrequency ablation improve survival in patients with hepatocellular carcinoma. |
| Q36563672 | Liver-directed therapies for patients with primary liver cancer and hepatic metastases |
| Q26829892 | Local ablation for hepatocellular carcinoma in taiwan |
| Q28078113 | Local ablative treatments for hepatocellular carcinoma: An updated review |
| Q37567808 | Local recurrence of hepatocellular carcinoma in the tumor blood drainage area following radiofrequency ablation |
| Q35152457 | Locally ablative therapies for primary and metastatic liver cancer. |
| Q37766546 | Loco-regional treatment of hepatocellular carcinoma |
| Q30400312 | Locoregional treatment for hepatocellular carcinoma: The best is yet to come |
| Q37240376 | Long-term outcome of percutaneous ethanol injection therapy for minimum-sized hepatocellular carcinoma |
| Q28236063 | Lyso-thermosensitive liposomal doxorubicin: a novel approach to enhance efficacy of thermal ablation of liver cancer |
| Q39720049 | Lyso-thermosensitive liposomal doxorubicin: an adjuvant to increase the cure rate of radiofrequency ablation in liver cancer |
| Q83971020 | MR-guided radiofrequency ablation using a wide-bore 1.5-T MR system: clinical results of 213 treated liver lesions |
| Q28258769 | Management of HCC |
| Q35771842 | Management of Hepatocellular Carcinoma: Current Status and Future Directions |
| Q29616230 | Management of hepatocellular carcinoma |
| Q37625446 | Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009. |
| Q36955647 | Management of hepatocellular carcinoma: Enlightening the gray zones. |
| Q46956055 | Management of hepatocellular carcinoma: treatment options and indications for orthotopic liver transplantation. |
| Q34681207 | Management of people with early- or very early-stage hepatocellular carcinoma: an attempted network meta-analysis. |
| Q38088585 | Management of small hepatocellular carcinoma in cirrhosis: focus on portal hypertension |
| Q33443502 | Meta-analysis of percutaneous radiofrequency ablation versus ethanol injection in hepatocellular carcinoma |
| Q26777664 | Microwave ablation of hepatocellular carcinoma |
| Q28079027 | Minimally invasive image-guided therapies for hepatocellular carcinoma |
| Q30468280 | Minimally invasive image-guided therapy for inoperable hepatocellular carcinoma: What is the evidence today? |
| Q34974386 | Minimally invasive local therapies for liver cancer |
| Q37640149 | Monopolar radiofrequency ablation using a dual-switching system and a separable clustered electrode: evaluation of the in vivo efficiency |
| Q64943233 | Multidisciplinary management of recurrent and metastatic hepatocellular carcinoma after resection: an international expert consensus. |
| Q26998606 | Multidisciplinary perspective of hepatocellular carcinoma: A Pacific Northwest experience |
| Q36636630 | Multidisciplinary treatment of patients with hepatocellular carcinoma |
| Q37384682 | Multimodal approaches to the treatment of hepatocellular carcinoma |
| Q42861829 | Multimodality treatment for hepatocellular carcinoma |
| Q45768262 | Multimodality treatment with conventional transcatheter arterial chemoembolization and radiofrequency ablation for unresectable hepatocellular carcinoma |
| Q38801422 | NCCN Guidelines Insights: Hepatobiliary Cancers, Version 1.2017 |
| Q35703937 | NCCN clinical practice guidelines in oncology: hepatobiliary cancers |
| Q36519032 | New aspects of diagnosis and therapy of hepatocellular carcinoma. |
| Q34647076 | New progress of non-surgical treatments for hepatocellular carcinoma |
| Q83974014 | Oblique approach for CT-guided liver radiofrequency ablation using multiplanar reformation images in hepatocellular carcinoma |
| Q33718963 | Outcomes for patients following hepatic resection of metastatic tumors from gastric cancer |
| Q55487080 | Percutaneous Ablation for Hepatocellular Carcinoma: Comparison of Various Ablation Techniques and Surgery. |
| Q33427579 | Percutaneous ablation for small hepatocellular carcinoma |
| Q24630594 | Percutaneous ethanol injection for hepatocellular carcinoma: 20-year outcome and prognostic factors |
| Q24186496 | Percutaneous ethanol injection or percutaneous acetic acid injection for early hepatocellular carcinoma |
| Q37226202 | Percutaneous ethanol injection therapy is comparable to radiofrequency ablation in hepatocellular carcinoma smaller than 1.5 cm: A matched case-control comparative analysis |
| Q35654638 | Percutaneous hepatic radiofrequency for hepatocellular carcinoma: results and outcome of 46 patients |
| Q43830759 | Percutaneous radiofrequency ablation as first-line treatment for small hepatocellular carcinoma: results and prognostic factors on long-term follow up. |
| Q79341963 | Percutaneous radiofrequency ablation for early-stage hepatocellular carcinoma as a first-line treatment: long-term results and prognostic factors in a large single-institution series |
| Q45951768 | Percutaneous radiofrequency ablation of hepatocellular carcinoma abutting the diaphragm and gastrointestinal tracts with the use of artificial ascites: safety and technical efficacy in 143 patients. |
| Q81018207 | Percutaneous radiofrequency ablation of hepatocellular carcinoma: analysis of 80 patients treated with two consecutive sessions |
| Q33157552 | Percutaneous radiofrequency ablation of hepatocellular carcinomas adjacent to the gallbladder with internally cooled electrodes: assessment of safety and therapeutic efficacy. |
| Q50527907 | Percutaneous radiofrequency ablation therapy for hepatocellular carcinoma: a proposed new grading system for the ablative margin and prediction of local tumor progression and its validation. |
| Q83394410 | Percutaneous thermal ablation of medium and large hepatocellular carcinoma: long-term outcome and prognostic factors |
| Q33280568 | Percutaneous treatment of hepatocellular carcinoma: what is the best technique? |
| Q24240216 | Percutanous ethanol injection or percutaneous acetic acid injection for early hepatocellular carcinoma |
| Q38959682 | Peretinoin as an adjuvant therapy for hepatocellular carcinoma |
| Q34977179 | Phase I dose-escalation study of proton beam therapy for inoperable hepatocellular carcinoma |
| Q40172995 | Potential role of vitamin K(2) as a chemopreventive agent against hepatocellular carcinoma |
| Q64931017 | Predicting recurrence following radiofrequency percutaneous ablation for hepatocellular carcinoma. |
| Q35535968 | Presentation and outcomes of hepatocellular carcinoma patients at a western centre |
| Q58571246 | Pretreatment Inflammation-Based Markers Predict Survival Outcomes in Patients with Early Stage Hepatocellular Carcinoma After Radiofrequency Ablation |
| Q38216004 | Prognostic factors for hepatocellular carcinoma recurrence |
| Q43882388 | Prognostic impact of treatment modalities on patients with single nodular recurrence of hepatocellular carcinoma |
| Q42922856 | Quality improvement guidelines for radiofrequency ablation of liver tumours |
| Q34544494 | RETRACTED: Systematic evaluation of percutaneous radiofrequency ablation versus percutaneous ethanol injection for the treatment of small hepatocellular carcinoma: a meta-analysis |
| Q51734417 | Racial and geographic disparities in the utilization of surgical therapy for hepatocellular carcinoma. |
| Q24201669 | Radiofrequency (thermal) ablation versus no intervention or other interventions for hepatocellular carcinoma |
| Q90472233 | Radiofrequency Ablation Combined With Transarterial Chemoembolization for Specially Located Small Hepatocellular Carcinoma |
| Q38351389 | Radiofrequency Ablation for the Treatment of Hepatocellular Carcinoma in Patients with Transjugular Intrahepatic Portosystemic Shunts |
| Q36152907 | Radiofrequency ablation combined with percutaneous ethanol injection for hepatocellular carcinoma: a systematic review and meta-analysis |
| Q42718820 | Radiofrequency ablation combined with resection enhances chance for curative treatment of hepatocellular carcinoma |
| Q44407577 | Radiofrequency ablation combined with transarterial chemoembolization for intermediate hepatocellular carcinoma |
| Q52929135 | Radiofrequency ablation combined with transarterial chemoembolization versus hepatectomy for patients with hepatocellular carcinoma within Milan criteria: a retrospective case-control study. |
| Q39034301 | Radiofrequency ablation combined with transcatheter therapy in rabbit VX2 liver tumors: effects and histopathological characteristics |
| Q38128370 | Radiofrequency ablation for hepatocellular carcinoma |
| Q30512830 | Radiofrequency ablation for hepatocellular carcinoma: 10-year outcome and prognostic factors. |
| Q50501938 | Radiofrequency ablation for hepatocellular carcinoma: the relationship between a new grading system for the ablative margin and clinical outcomes. |
| Q36326256 | Radiofrequency ablation for hepatocellular carcinoma: use of low vs maximal radiofrequency power |
| Q37296885 | Radiofrequency ablation is superior to ethanol injection in early-stage hepatocellular carcinoma irrespective of tumor size |
| Q34483032 | Radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation. |
| Q42123495 | Radiofrequency ablation of hepatocellular carcinoma in patients with and without cirrhosis |
| Q37317451 | Radiofrequency ablation of hepatocellular carcinoma sized > 3 and ≤ 5 cm: is ablative margin of more than 1 cm justified? |
| Q30478030 | Radiofrequency ablation of hepatocellular carcinoma: Current status |
| Q30473747 | Radiofrequency ablation of hepatocellular carcinoma: a literature review |
| Q41683441 | Radiofrequency ablation of hepatocellular carcinoma: pros and cons |
| Q34553541 | Radiofrequency ablation of small hepatocellular carcinoma with intravenous pegylated liposomal doxorubicin |
| Q46526872 | Radiofrequency ablation versus ethanol injection for early hepatocellular carcinoma: A randomized controlled trial |
| Q35273624 | Radiofrequency ablation versus laser ablation for the treatment of small hepatocellular carcinoma in cirrhosis: a randomized trial. |
| Q35166558 | Radiofrequency ablation versus percutaneous ethanol injection for hepatocellular carcinoma: a meta-analysis of randomized controlled trials |
| Q42364566 | Radiofrequency ablation versus stereotactic body radiotherapy for small hepatocellular carcinoma: a Markov model-based analysis |
| Q37379002 | Radiofrequency thermal ablation vs. percutaneous ethanol injection for small hepatocellular carcinoma in cirrhosis: meta-analysis of randomized controlled trials. |
| Q91918989 | Radiotherapy for Hepatocellular Carcinoma Results in Comparable Survival to Radiofrequency Ablation: A Propensity Score Analysis |
| Q30460837 | Recent advances in radiofrequency ablation for the management of hepatocellular carcinoma |
| Q43670704 | Recurrences of hepatocellular carcinoma following complete remission by transarterial chemoembolization or radiofrequency therapy: Focused on the recurrence patterns |
| Q35692190 | Refusal of cancer-directed surgery strongly impairs survival of patients with localized hepatocellular carcinoma |
| Q45400036 | Repeated radiofrequency ablation for the distant recurrence in the liver in patients with chronic hepatitis C virus infection achieving long-term survival |
| Q47625733 | Response to radiofrequency ablation of pulmonary tumours: a prospective, intention-to-treat, multicentre clinical trial (the RAPTURE study). |
| Q43806466 | Risk factors for local and distant recurrence of hepatocellular carcinomas after local ablation therapies |
| Q99566275 | Role of imaging in management of hepatocellular carcinoma: surveillance, diagnosis, and treatment response |
| Q30417048 | Role of local ablative therapy for hepatocellular carcinoma |
| Q41128609 | Role of radiofrequency ablation in the treatment of small hepatocellular carcinoma |
| Q37183205 | Role of radiofrequency ablation in unresectable hepatocellular carcinoma: An Indian experience |
| Q37278194 | Safety and efficacy of lamivudine after radiofrequency ablation in patients with hepatitis B virus-related hepatocellular carcinoma. |
| Q89474952 | Safety and efficacy of stereotactic radiofrequency ablation for very large (≥8 cm) primary and metastatic liver tumors |
| Q58687486 | Screening for hepatocellular carcinoma |
| Q90467572 | Serum levels of ferritin do not affect the prognosis of patients with hepatocellular carcinoma undergoing radiofrequency ablation |
| Q37627643 | Single HCC between 2 and 5 cm: the grey zone: surgeon's perspective |
| Q37627645 | Single HCC smaller than 2 cm: surgery or ablation: interventional oncologist's perspective |
| Q36408339 | Single hepatocellular carcinoma ranging from 3 to 5 cm: radiofrequency ablation or resection? |
| Q37998929 | Small hepatocellular carcinomas: ultrasonography guided percutaneous radiofrequency ablation |
| Q90682144 | Stereotactic Radiofrequency Ablation of Liver Tumors in Octogenarians |
| Q53099009 | Stereotactic ablative body radiotherapy for previously untreated solitary hepatocellular carcinoma. |
| Q45866946 | Stereotactic body radiation therapy combined with transcatheter arterial chemoembolization for small hepatocellular carcinoma |
| Q57987901 | Stereotactic body radiation therapy for inoperable hepatocellular carcinoma as a local salvage treatment after incomplete transarterial chemoembolization |
| Q36863488 | Strategies for the management of hepatocellular carcinoma |
| Q84948447 | Strong CD8(+) T-cell responses against tumor-associated antigens prolong the recurrence-free interval after tumor treatment in patients with hepatocellular carcinoma |
| Q34959556 | Superior long-term outcomes after surgery in child-pugh class a patients with single small hepatocellular carcinoma compared to radiofrequency ablation |
| Q87279251 | Surgical resection versus open-approach radiofrequency ablation for small hepatocellular carcinomas within Milan criteria after successful transcatheter arterial chemoembolization |
| Q84590882 | Surgical treatment of hepatocellular carcinoma |
| Q51103360 | Surveillance for early diagnosis of hepatocellular carcinoma: is it effective in intermediate/advanced cirrhosis? |
| Q34584992 | Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: Is resection still the treatment of choice? |
| Q36235400 | Switching bipolar hepatic radiofrequency ablation using internally cooled wet electrodes: comparison with consecutive monopolar and switching monopolar modes |
| Q33964077 | Systematic review and meta-analysis of survival and disease recurrence after radiofrequency ablation for hepatocellular carcinoma |
| Q34595503 | Systematic review of radiofrequency ablation versus percutaneous ethanol injection for small hepatocellular carcinoma up to 3 cm |
| Q33391168 | Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies |
| Q36476765 | Systematic review: evidence-based management of hepatocellular carcinoma--an updated analysis of randomized controlled trials. |
| Q33400353 | Systemic combination therapy of intravenous continuous 5-fluorouracil and subcutaneous pegylated interferon alfa-2a for advanced hepatocellular carcinoma. |
| Q46027563 | The 6th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2015): Evidence and Consensus on HCC Management. |
| Q38970852 | The Effectiveness of Multiple Electrode Radiofrequency Ablation in Patients with Hepatocellular Carcinoma with Lesions More than 3 cm in Size and Barcelona Clinic Liver Cancer Stage A to B2. |
| Q38217657 | The clinical management of hepatocellular carcinoma in the United States, Europe, and Asia: a comprehensive and evidence-based comparison and review. |
| Q37874475 | The current role of minimally invasive therapies in the management of liver tumors |
| Q84124540 | The influence of hepatitis B DNA level and antiviral therapy on recurrence after initial curative treatment in patients with hepatocellular carcinoma |
| Q38055031 | The laparoscopic approach for radiofrequency ablation of hepatocellular carcinoma--indication, technique and results. |
| Q37625811 | The management of patients awaiting liver transplantation |
| Q58787250 | The prognostic analysis of different metastatic patterns in advanced liver cancer patients: A population based analysis |
| Q40201286 | The risk of early occurrence and recurrence of hepatocellular carcinoma in hepatitis C-infected patients treated with direct-acting antivirals with and without pegylated interferon: A Belgian experience. |
| Q51735339 | The role of definitive local treatment in metastatic hepatocellular carcinoma patients: A SEER-based study. |
| Q36662565 | Therapeutic efficacy and safety of percutaneous ethanol injection with or without combined radiofrequency ablation for hepatocellular carcinomas in high risk locations |
| Q27016138 | Therapeutic response assessment of RFA for HCC: contrast-enhanced US, CT and MRI. |
| Q33323261 | Thermal ablation of hepatocellular carcinoma. |
| Q36046058 | Transarterial chemoembolization (TACE) plus percutaneous ethanol injection (PEI) for the treatment of unresectable hepatocellular carcinoma: a meta-analysis of randomized controlled trials |
| Q37038364 | Transcatheter arterial chemoembolization and percutaneous ethanol injection for Hepatocellular carcinoma: a retrospective review of the Veterans Affairs Caribbean Healthcare System |
| Q51766175 | Transcatheter arterial chemoembolization plus radiofrequency ablation therapy for early stage hepatocellular carcinoma: comparison with surgical resection. |
| Q46149617 | Treating hepatocellular carcinoma without liver transplantation |
| Q33635364 | Treatment Options of Metastatic Brain Tumors from Hepatocellular Carcinoma: Surgical Resection vs. Gamma Knife Radiosurgery vs. Whole Brain Radiation Therapy |
| Q35037545 | Treatment for hepatocellular carcinoma in Japan over the last three decades: Our experience and published work review |
| Q36833328 | Treatment of HCC in patients awaiting liver transplantation |
| Q89769437 | Treatment of Intermediate-Stage Hepatocellular Carcinoma in Japan: Position of Curative Therapies |
| Q38549768 | Treatment of Liver Cancer |
| Q58021482 | Treatment of early hepatocellular carcinoma: Towards personalized therapy |
| Q48015556 | Treatment of hepatocellular carcinoma using internally cooled electrodes. A prospective comparison of modified automated vs. manual pulsed radiofrequency algorithms |
| Q26865456 | Treatment of hepatocellular carcinoma: Steps forward but still a long way to go |
| Q38295870 | Treatment of hepatocellular carcinoma: beyond international guidelines. |
| Q38685608 | Treatment of hepatocellular carcinoma: beyond international guidelines. |
| Q38096477 | Treatment of hepatocellular carcinoma: present and future |
| Q37345911 | Treatment options for hepatocellular carcinoma |
| Q51028325 | Treatment strategy for early hepatocellular carcinomas: comparison of radiofrequency ablation with or without transcatheter arterial chemoembolization and surgical resection. |
| Q89766272 | Trends and outcomes of transarterial chemoembolization in hepatocellular carcinoma: a national survey |
| Q37356216 | Type 1 interferon receptor in peripheral blood mononuclear cells may predict response to intra-arterial 5-fluorouracil + interferon therapy for advanced hepatocellular carcinoma |
| Q36561581 | Ultrasonogram of hepatocellular carcinoma is associated with outcome after radiofrequency ablation |
| Q37466198 | Ultrasound surveillance for early detection of hepatocellular carcinoma among patients with chronic hepatitis C. |
| Q47137057 | Ultrasound-guided percutaneous microwave ablation assisted by three-dimensional visualization operative treatment planning system and percutaneous transhepatic cholangial drainage with intraductal chilled saline perfusion for larger hepatic hilum he |
| Q40572579 | Ultrasound-guided percutaneous microwave ablation for hepatocellular carcinoma: clinical outcomes and prognostic factors |
| Q34571160 | Updates in the management of hepatocellular carcinoma |
| Q41298514 | Use of radiofrequency ablation in the treatment of hepatocellular carcinoma: Experience of ablation protocols |
| Q54988323 | Utility of endoscopic ultrasound and endoscopy in diagnosis and management of hepatocellular carcinoma and its complications: What does endoscopic ultrasonography offer above and beyond conventional cross-sectional imaging? |
| Q52955178 | Value of Nonrigid Registration of Pre-Procedure MR with Post-Procedure CT After Radiofrequency Ablation for Hepatocellular Carcinoma. |
| Q42590254 | Well-differentiated hepatocellular carcinoma smaller than 15 mm in diameter totally eradicated with percutaneous ethanol injection instead of radiofrequency ablation |
| Q57763672 | What Is the Best Time to Evaluate Treatment Response after Radiofrequency Ablation of Hepatocellular Carcinoma Using Contrast-Enhanced Sonography? |
| Q35613914 | Which is more cost-effective under the MELD system: primary liver transplantation, or salvage transplantation after hepatic resection or after loco-regional therapy for hepatocellular carcinoma within Milan criteria? |
| Q81949821 | [Liver transplant in patients with hepatocellular carcinoma] |
| Q87421151 | [National S3 guidelines on hepatocellular carcinoma] |
| Q53180274 | [Radiofrequency ablation - is a technique finished?]. |
| Q79424363 | [Regional therapy of liver tumors] |
| Q53463288 | [The impact of large vessel proximity on effectiveness of radiofrequency ablation of hepatocellular carcinoma: a controlled study] |
Search more.